Pancreatic Microbiome May Hold the Key To Better Treatment
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Aiming to Improve Immunotherapy for Pancreatic Cancer
One particular area of interest: improving immunotherapy, a treatment that has shown to be effective in many cancers but, so…
Targeting AXL May Improve Chemotherapy for Pancreatic Cancer
Dr. Shaalan Beg describes a clinical trial using the kinase inhibitor bemcentinib along with chemotherapy as a way to slow down or stop pancreatic cancer.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
But newer approaches like targeted therapies take aim at very specific genetic changes and the proteins within cancer cells that…
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
